CAP-1002 - Emerging Insight and Market Forecast - 2030

Overview

CAP-1002 - Emerging Insight and Market Forecast - 2030 report by the publisher outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the CAP-1002 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

CAP 1002 is an allogeneic cardiosphere-derived stem cell (CDC) therapeutic, being developed by Capricor Therapeutics (formerly Capricor Inc), for the treatment of Duchenne muscular dystrophy; Heart failure; Myocardial infarction, COVID 2019 infections. Capricor's core therapeutic technology (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor's scientific founder, Dr. Eduardo Marbán. Since the initial publication in 2007, CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 150 human subjects across several clinical trials. CAP-1002 consists of allogeneic “off-the-shelf” cardiosphere-derived cells, or CDCs, a type of cardiac cell therapy that has been shown in pre-clinical and clinical studies to exert potent immunomodulatory activity. It is being investigated for its potential to modify the immune system's activity to encourage cellular regeneration. The cells function by releasing exosomes that are taken up largely by macrophages and T-cells and begin a cycle of repair. CAP-1002 has been granted orphan drug designation by the FDA for the treatment of DMD.

Scope of the report

The report provides insights into:

• A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug marketed details across the United States, Europe and Japan.
• The report also covers the patent's information with expiry timeline around CAP-1002.
• The report contains historical and forecasted sales for CAP-1002 till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
• The report also features the SWOT analysis with analyst insights and key findings of CAP-1002.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CAP-1002 Analytical Perspective

In-depth CAP-1002 Market Assessment

This report provides a detailed market assessment of CAP-1002 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

CAP-1002 Clinical Assessment

The report provides the clinical trials information of CAP-1002 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights

• In the coming years, the market scenario for CAP-1002 is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence CAP-1002 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other approved products for the disease are giving market competition to CAP-1002 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of CAP-1002.
• Our in-depth analysis of the sales data of CAP-1002 from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CAP-1002 in the market.

Key Questions Answered

• What is the prescribed dosage and strengths of CAP-1002 are available in the market?
• What are the common adverse reactions or side effects of CAP-1002?
• What is the product type, route of administration and mechanism of action of CAP-1002?
• What are the chemical specifications of CAP-1002?
• How are the clinical trials diversified on the basis of the trial status?
• What is the history of CAP-1002, and what is its future?
• What are the marketed details of CAP-1002 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• How many patents have been granted to CAP-1002 and when these patents will get expire?
• What are the pros (benefits) and cons (disadvantages) of CAP-1002?
• In which countries CAP-1002 got approval and when it gets launched?
• What are the clinical trials are currently ongoing for CAP-1002?
• How the safety and efficacy results determined the approval of CAP-1002?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CAP-1002 development?
• What are the key designations that have been granted to CAP-1002?
• What is the historical and forecasted market scenario of CAP-1002?
• How is the market trend of CAP-1002 is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
• What are the other approved products available and how these are giving competition to CAP-1002?
• Which are the late-stage emerging therapies under development for the treatment of the indicated condition?